Lattice Biologics (TSXV:LBL.H) Total Liabilities : C$0.62 Mil (As of Jun. 2021)

View and export this data going back to 1995. Start your Free Trial

What is Lattice Biologics Total Liabilities?

Lattice Biologics's Total Liabilities for the quarter that ended in Jun. 2021 was C$0.62 Mil.

Lattice Biologics's quarterly Total Liabilities declined from Dec. 2020 (C$12.22 Mil) to Mar. 2021 (C$2.80 Mil) and declined from Mar. 2021 (C$2.80 Mil) to Jun. 2021 (C$0.62 Mil).

Lattice Biologics's annual Total Liabilities increased from Sep. 2018 (C$10.93 Mil) to Sep. 2019 (C$11.37 Mil) and increased from Sep. 2019 (C$11.37 Mil) to Sep. 2020 (C$12.46 Mil).

Lattice Biologics Total Liabilities Historical Data

The historical data trend for Lattice Biologics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Total Liabilities Chart

Lattice Biologics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Sep16

Sep17

Sep18

Sep19

Sep20

Total Liabilities

Get a 7-Day Free Trial

13.77

9.47

10.93

11.37

12.46

Lattice Biologics Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Total Liabilities	Get a 7-Day Free Trial															12.61	12.46	12.22	2.80	0.62

Lattice Biologics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lattice Biologics's Total Liabilities for the fiscal year that ended in Sep. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	10.362	+	(1.175	+	0.924
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	12.46

Total Liabilities	=	Total Assets (A: Sep. 2020 )	-	Total Equity (A: Sep. 2020 )
	=	3.993	-	-8.469
	=	12.46

Lattice Biologics's Total Liabilities for the quarter that ended in Jun. 2021 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.618	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.62

Total Liabilities	=	Total Assets (Q: Jun. 2021 )	-	Total Equity (Q: Jun. 2021 )
	=	0.741	-	0.123
	=	0.62

Lattice Biologics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Lattice Biologics (TSXV:LBL.H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (TSXV:LBL.H) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714

Website

http://www.latticebiologics.com

Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (TSXV:LBL.H) Headlines

No Headlines